This study evaluated the in vitro antimicrobial activity of telavancin against a large collection of Gram-positive pathogens of clinical importance, which were collected worldwide from 2015 through 2017, including methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci, Enterococcus spp., β-hemolytic streptococci (BHS), Streptococcus pneumoniae, and viridans group streptococci (VGS). This report completes 7 years of continuous surveillance data for telavancin using the approved reference method for in vitro testing methodology that includes the addition of polysorbate 80. For isolates collected from 2015 through 2017, telavancin exhibited potent activity against the following species and groups that have Clinical and Laboratory Standards Institute (CLSI)-approved interpretive criteria: MRSA (MIC₉₀ value, 0.06 μg/mL; 100% susceptible), vancomycin-susceptible Enterococcus faecalis (MIC₉₀ value, 0.25 μg/mL; 99.9% susceptible), BHS (MIC₉₀ value, 0.03 μg/mL; 100% susceptible), and VGS (MIC₉₀ value, 0.03 μg/mL; 99.0% susceptible). Importantly, telavancin maintained excellent antimicrobial activity against multidrug-resistant subsets of these pathogen groups and against ceftaroline-nonsusceptible (telavancin MIC₉₀ value, 0.06 μg/mL; 100% susceptible) and ceftaroline-resistant (telavancin MIC₉₀ value, 0.12 μg/mL; 100% susceptible) S. aureus isolates.

中文翻译：

---

特拉万星对全球革兰氏阳性病原体（包括耐多药分离株）的体外抗菌活性进行了测试（2015-2017）。

这项研究评估了特拉万星对大量具有临床重要性的革兰氏阳性病原体的体外抗菌活性，该病原体于2015年至2017年在全球范围内收集，包括耐甲氧西林的金黄色葡萄球菌（MRSA），凝固酶阴性葡萄球菌，肠球菌。 ，β-溶血性链球菌（BHS），肺炎链球菌和绿腐菌类链球菌（VGS）。本报告使用批准的体外参考方法完成了替拉万星7年的连续监测数据测试方法，其中包括添加聚山梨酯80。对于从2015年到2017年收集的分离株，特拉万星对具有临床和实验室标准协会（CLSI）批准的解释标准的以下物种和群体表现出强大的活性：MRSA（MIC ₉₀值，0.06 μg/ mL; 100％易感），万古霉素易感粪肠球菌（MIC ₉₀值，0.25μg/ mL; 99.9％易感），BHS（MIC ₉₀值，0.03μg/ mL; 100％易感）和VGS（MIC ₉₀值0.03μg/ mL; 99.0％易感）。重要的是，特拉万星对这些病原体的多药耐药亚群和对头孢洛林不敏感的药物（特拉万星MIC₉₀值，0.06μg/ mL; 100％易感）和头孢洛林耐药性（特拉万星MIC ₉₀值，0.12μg/ mL; 100％易感）金黄色葡萄球菌分离株。